<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031638</url>
  </required_header>
  <id_info>
    <org_study_id>AB2015THYROID</org_study_id>
    <nct_id>NCT04031638</nct_id>
  </id_info>
  <brief_title>Thyroid Cancer Database</brief_title>
  <official_title>Prospective and Retrospective Thyroid Cancer Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid cancer database collects clinical and laboratory data from patients with a thyroid
      tumor who received radioactive Iodine treatment. This database only records information based
      on patients' medical files in a structured manner.

      Thyroid database is used for retrospective non-interventional research projects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2000</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient survival</measure>
    <time_frame>10 years</time_frame>
    <description>Overall survival and evolution over years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of patient and treatment characteristics</measure>
    <time_frame>10 years</time_frame>
    <description>Collection of patient and treatment characteristics over years, to set up prospective and retrospective studies</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment</condition>
  <arm_group>
    <arm_group_label>Radioactive Iodine treatment for thyroid cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radioactive Iodine treatment</intervention_name>
    <description>Patients with a thyroid tumor who received radioactive Iodine treatment.</description>
    <arm_group_label>Radioactive Iodine treatment for thyroid cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a thyroid tumor who received radioactive Iodine treatment in Centre Georges
        Francois Leclerc, Dijon, France
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a thyroid tumor (metastatic or not)

          -  patients who received radioactive Iodine treatment.

          -  age &gt;= 18

        Exclusion Criteria:

          -  Objection to collect medical data records
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AURELIE BERTAUT, MD, PhD</last_name>
    <phone>+33 3 80 73 77 84</phone>
    <email>ABertaut@cgfl.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Methodology, Biostatistics and Data Management</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AURELIE BERTAUT, MD, PhD</last_name>
      <phone>+33 3 80 73 77 84</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid cancer, Iodine treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

